Home > Insider Trading > Filing (0000899243-21-022069)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1847903	Centessa Pharmaceuticals Plc	CNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1863418	L Tia Bush	C/O Centessa Pharmaceuticals Plc 3Rd Fl., 1 Ashley Rd, Altrincham Cheshire X0 WA14 2DT	Chief Quality Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2021-06-02	3,000	$20.00	3,000	No	4	P	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Share Option (right to buy)	Acquisiton	2021-05-07	500,338	$0.00	500,338	$9.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
500,338		2031-05-07	No	4	A	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter..
Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.